Herbal supplement Ginkgo doesn’t stop Alzheimer’s

By Will Dunham

WASHINGTON (Reuters) - The widely used herbal supplement Ginkgo biloba does not appear to prevent Alzheimer’s disease in healthy elderly people or those with mild cognitive impairment, U.S. researchers said on Tuesday.

The study involved 3,069 people age 75 or older at five U.S. locations who were tracked for six years on average, half taking twice-daily doses of 120 milligrams of extract from the leaves of the ginkgo tree and the rest taking a placebo.

Those who took the ginkgo were no more or less likely to develop Alzheimer’s or any type of dementia, the researchers wrote in the Journal of the American Medical Association.

Dr. Steven DeKosky, dean of the University of Virginia School of Medicine who led the study, said he was disappointed in the results, citing early indications that ginkgo has antioxidant and other properties that might preserve memory.

“At this point in time, I wouldn’t tell anybody to take the medication in hopes that it would work (to prevent Alzheimer’s),” DeKosky, who was at the University of Pittsburgh when the study was conducted, said in a telephone interview.

“If they want to continue taking it — because it’s not toxic and not expensive — they probably aren’t going to hurt themselves other than spending the money,” DeKosky added.

Ginkgo is one of the top-selling herbal supplements, used by people with the aim of improving memory and cognition and other purposes. This was the largest and most rigorous study to date on whether it would stave off Alzheimer’s, experts said.

The people entered the study with either no cognitive problems or only mild impairment. Eighteen percent in the ginkgo group and 16 percent in the placebo group were diagnosed with Alzheimer’s or other dementia during the study.


DeKosky said he could not rule out that ginkgo might have shown some benefit in preventing Alzheimer’s if the study had gone on longer because progression from initial brain changes to clinical dementia takes many years.

There is no medication currently approved to avert the development of Alzheimer’s disease, the most common form of dementia in the elderly.

Dr. Murali Doraiswamy of Duke University Medical Center in Durham, North Carolina, noted that other Alzheimer’s prevention failures include statins, estrogen, anti-inflammatory drugs, vitamin E and drugs called cholinesterase inhibitors.

Doraiswamy, a memory expert who was not part of the study, said the findings will lead him to actively discourage people from taking ginkgo with the aim of preventing Alzheimer’s.

Alzheimer’s is incurable. It slowly progresses from mild memory loss to severe brain damage and death. It is expected to become even more common as populations age in many countries.

“Alzheimer’s, by its very nature, tends to breed desperation, and that will direct some people to try almost anything. Here, at least, we have some evidence that it’s probably worth your while to find something else than ginkgo,” Bill Thies of the Alzheimer’s Association advocacy group said.  Continued…


Related Posts:

NEW YORK (Reuters Health) - Although often billed as a memory and cognition enhancing product, the medicinal herb Ginkgo biloba does not stave off cognitive decline or help prevent dementia and Alzheimer’s disease, according to a report in the Journal of the American Medical Association this week. In the Ginkgo Evaluation of Memory (GEM) Study, use

Full Post: Ginkgo biloba not useful in preventing dementia

LONDON (Reuters) - Mentally demanding jobs and more education appear to protect people from the memory loss associated with Alzheimer’s disease, Italian researchers said on Monday. The findings bolster the previous research about Alzheimer’s and other forms of brain impairment, said Valentina Garibotto of the San Raffaele University and Scientific Institute and the National Institute of

Full Post: Education protects against Alzheimer’s impact

By Will Dunham WASHINGTON (Reuters) - High doses of B vitamins failed to slow cognitive decline in people with Alzheimer’s disease, dashing the hopes for a new weapon against the fatal, mind-robbing ailment, U.S. researchers said on Tuesday. Experts had viewed B vitamins as a potential way to lower the risk of Alzheimer’s disease or slow its

Full Post: B vitamins fail in U.S. Alzheimer’s disease study

By Will Dunham WASHINGTON (Reuters) - Brain scans of people with an abnormality that is a hallmark of Alzheimer’s disease are strengthening the notion that greater education levels somehow protect against this common form of dementia. People with more education did better on memory and problem solving tests than others with similar amounts of brain plaques related

Full Post: Education blunts effects of Alzheimer’s: study

LONDON (Reuters) - Antipsychotic drugs prescribed to treat aggression in older Alzheimer’s patients appear to significantly raise their risk of dying prematurely, British researchers said Friday. The results from the first long-term study on the effect of the medicines on people with Alzheimer’s highlights the need to seek less harmful treatments for many of these patients,

Full Post: Antipsychotics for Alzheimer’s up death risk: study

Site Navigation

Most Read



  • kinwrite.com@gmail.com